UA26874C2 - Пареhтеральhа фармацевтичhа композиція - Google Patents

Пареhтеральhа фармацевтичhа композиція

Info

Publication number
UA26874C2
UA26874C2 UA95062794A UA95062794A UA26874C2 UA 26874 C2 UA26874 C2 UA 26874C2 UA 95062794 A UA95062794 A UA 95062794A UA 95062794 A UA95062794 A UA 95062794A UA 26874 C2 UA26874 C2 UA 26874C2
Authority
UA
Ukraine
Prior art keywords
human insulin
lys
phenol
pharmaceutical composition
parenteral pharmaceutical
Prior art date
Application number
UA95062794A
Other languages
English (en)
Russian (ru)
Inventor
Дайан Лі Бейкейса
Дайан Ли Бейкейса
Девід Неттлешип Бремс
Девид Неттлешип Бремс
Брюс Хілл Френк
Брюс Хилл Френк
Генрі Екен Хевел
Генри Экен Хевел
Аллен Хьюард Пекар
Original Assignee
Елі Ліллі Енд Компані
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22989969&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA26874(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Елі Ліллі Енд Компані, Эли Лилли Энд Компани filed Critical Елі Ліллі Енд Компані
Publication of UA26874C2 publication Critical patent/UA26874C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Винахід стосується мономерних аналогів людського інсуліну. Композиція включає комплекс, аналог людського інсуліну, що містить: шість молекул людського інсуліну, де Pro у позиції В28 заміщений Asp, Lys, Leu, Val або Ala; і Lys у позиції В29 є Lys або заміщений Pro; des(В28-ВЗО) -людський інсулін; або dез(В27) -людськийінсулін; два іони цинку і, щонайменше, три молекули фенолового похідного, вибраного з групи, що складається з н-крезолу, фенолу або суміші --крезолу і фенолу.
UA95062794A 1994-06-16 1995-06-14 Пареhтеральhа фармацевтичhа композиція UA26874C2 (uk)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/260,634 US5474978A (en) 1994-06-16 1994-06-16 Insulin analog formulations

Publications (1)

Publication Number Publication Date
UA26874C2 true UA26874C2 (uk) 1999-12-29

Family

ID=22989969

Family Applications (1)

Application Number Title Priority Date Filing Date
UA95062794A UA26874C2 (uk) 1994-06-16 1995-06-14 Пареhтеральhа фармацевтичhа композиція

Country Status (39)

Country Link
US (1) US5474978A (uk)
JP (2) JP3171541B2 (uk)
KR (1) KR100382326B1 (uk)
CN (1) CN1105576C (uk)
AT (1) AT408720B (uk)
BE (1) BE1009408A5 (uk)
BR (1) BR9502795A (uk)
CA (1) CA2151560C (uk)
CH (2) CH689250A5 (uk)
CO (1) CO4410203A1 (uk)
CZ (1) CZ287484B6 (uk)
DE (1) DE19521720B4 (uk)
DK (1) DK173015B1 (uk)
ES (1) ES2091727B1 (uk)
FI (1) FI118207B (uk)
FR (2) FR2721214B1 (uk)
GB (1) GB2291427B (uk)
GR (1) GR1003004B (uk)
HK (1) HK1015138A1 (uk)
HU (1) HU227240B1 (uk)
IE (1) IE68853B1 (uk)
IL (1) IL114151A (uk)
IT (1) IT1276723B1 (uk)
LU (1) LU88626A1 (uk)
MY (1) MY115631A (uk)
NL (1) NL1000566C2 (uk)
NO (1) NO322128B1 (uk)
NZ (1) NZ272359A (uk)
PE (1) PE19496A1 (uk)
PL (1) PL181310B1 (uk)
PT (1) PT101722B (uk)
RO (1) RO113530B1 (uk)
RS (1) RS49577B (uk)
RU (1) RU2152399C2 (uk)
SE (1) SE509052C2 (uk)
SI (1) SI9500200A (uk)
TW (1) TW421596B (uk)
UA (1) UA26874C2 (uk)
ZA (1) ZA954943B (uk)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5352050A (en) * 1992-07-27 1994-10-04 Choate John I M Keyboard arrangement to maximize typing speed and ease of transition from a QWERTY keyboard
US5836705A (en) * 1992-07-27 1998-11-17 Choate; John I. M. Keyboard arrangement to maximize typing speed and data entry and to ease transition from a qwerty keyboard
US5498088A (en) * 1992-07-27 1996-03-12 Choate; John I. M. Keyboard arrangement to maximize typing speed and ease of transition from a qwerty keyboard
DK72793D0 (da) * 1993-06-21 1993-06-21 Novo Nordisk As Nyt produkt
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5547929A (en) * 1994-09-12 1996-08-20 Eli Lilly And Company Insulin analog formulations
US5693609A (en) * 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
YU18596A (sh) * 1995-03-31 1998-07-10 Eli Lilly And Company Analogne formulacije monomernog insulina
DE69630527T2 (de) * 1995-06-30 2004-08-05 Novo Nordisk A/S Vorbeugung einer krankheit mit diabetes charakter
CN1120019C (zh) * 1996-06-20 2003-09-03 诺沃挪第克公司 含NaCl的胰岛素制品
PE79099A1 (es) * 1997-06-13 1999-08-24 Lilly Co Eli Formulaciones de insulina estables
WO1999021573A1 (en) 1997-10-24 1999-05-06 Eli Lilly And Company Fatty acid-acylated insulin analogs
CO4970787A1 (es) * 1997-12-23 2000-11-07 Lilly Co Eli Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea
AU1870099A (en) * 1998-01-09 1999-07-26 Novo Nordisk A/S Stabilised insulin compositions
ATE277630T1 (de) * 1998-10-16 2004-10-15 Novo Nordisk As Stabile konzentrierte insulin präparationen zur pulmonaren verabreichung
CA2346884A1 (en) * 1998-10-16 2000-04-27 Novo Nordisk A/S Insulin preparations for pulmonary delivery containing menthol
US6635617B1 (en) 1998-10-16 2003-10-21 Novo Nordisk A/S Insulin preparations for pulmonary delivery containing menthol
US6211144B1 (en) 1998-10-16 2001-04-03 Novo Nordisk A/S Stable concentrated insulin preparations for pulmonary delivery
US6489292B1 (en) 1998-11-18 2002-12-03 Novo Nordisk A/S Stable aqueous insulin preparations without phenol and cresol
JP2002529514A (ja) * 1998-11-18 2002-09-10 ノボ ノルディスク アクティーゼルスカブ フェノール及びクレゾールを要さない安定なインスリン水性調製物
US20040214747A1 (en) * 1999-01-06 2004-10-28 Dimarchi Richard Dennis Method for administering monomeric insulin
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
AU2001220765A1 (en) 2000-01-24 2001-07-31 Medtronic Minimed, Inc. Mixed buffer system for stabilizing polypeptide formulations
WO2002009639A2 (en) * 2000-07-31 2002-02-07 Bar Ilan University Methods and pharmaceutical compositions for healing wounds
US20040037828A1 (en) 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
US6737401B2 (en) * 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
AU2003223158B2 (en) 2002-01-09 2008-01-17 Emisphere Technologies, Inc. Polymorphs of sodium 4-[(4-chloro-2-hydroxybenzoyl)amino]butanoate
US20030211976A1 (en) * 2002-03-07 2003-11-13 Andreasen Kasper Huus Polyamino acid-based particle insulin formulation
US20040005999A1 (en) * 2002-03-07 2004-01-08 Andreasen Kasper Huus Polyamino acid-based particle insulin preparation
DE10227232A1 (de) * 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
US20060258561A1 (en) * 2003-03-13 2006-11-16 Novo Nordisk A/S Novel NPH insulin preparations
CA2528741A1 (en) 2003-06-17 2004-12-23 Sembiosys Genetics Inc. Methods for the production of insulin in plants
PL1648933T3 (pl) * 2003-07-25 2010-01-29 Conjuchem Biotechnologies Inc Długo działające pochodne insuliny i związane z tym sposoby
US7658721B2 (en) * 2004-01-16 2010-02-09 Biodel Inc. Sublingual drug delivery device
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
US20080085298A1 (en) * 2004-03-12 2008-04-10 Biodel, Inc. Rapid Mucosal Gel or Film Insulin Compositions
US20080096800A1 (en) * 2004-03-12 2008-04-24 Biodel, Inc. Rapid mucosal gel or film insulin compositions
SG153039A1 (en) 2004-05-06 2009-06-29 Emisphere Tech Inc Crystalline polymorphic forms of monosodium n-[8- (2hydroxybenzoyl)amino]caprylate
WO2005117854A2 (en) * 2004-05-14 2005-12-15 Emisphere Technologies, Inc. Aryl ketone compounds and compositions for delivering active agents
WO2005115341A2 (en) * 2004-05-27 2005-12-08 Advanced Bionutrition Corporation Microparticles for oral delivery
CN105801686B (zh) 2004-07-19 2020-04-07 比奥孔有限公司 胰岛素-低聚物共轭物、制剂及其用途
JP2008509145A (ja) 2004-08-03 2008-03-27 エミスフィアー テクノロジーズ インコーポレイテッド 抗糖尿病性経口インスリン−ビグアニドの組み合わせ
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
EP1781257B1 (en) * 2004-08-13 2018-12-19 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
BRPI0516464B8 (pt) * 2004-10-05 2021-05-25 Novo Nordisk As método para a preparação de um produto farmacêutico
WO2006053906A1 (en) 2004-11-22 2006-05-26 Novo Nordisk A/S Soluble, stable insulin-containing formulations with a protamine salt
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
WO2006093222A1 (ja) * 2005-03-02 2006-09-08 Ajinomoto Co., Inc. インスリンの多量体形成阻害剤
CA2625674C (en) 2005-08-29 2015-04-14 Healor Ltd. Methods and compositions for prevention and treatment of diabetic and aged skin
BRPI0616558B1 (pt) 2005-09-19 2021-09-08 Emisphere Technologies, Inc Forma i do sal dissódico do ácido n-(5-clorossaliciloil)-5-aminocapróico, monohidrato cristalino do sal dissódico do ácido n-(5-saliciloil)-8-aminocaprílico, forma ii do sal dissódico do ácido n-(5-clorossaliciloil)-5-aminocapróico, solvato de etanol cristalino do sal dissódico do ácido n-(5-salicioloil)-8-aminocaprílico, forma iii do sal dissódico do ácido n-(5-clorossaliciloil)-5- aminocapróico, octahidrato do sal dissódico do ácido n-(5-saliciloil)-8-aminocaprílico, monohidrato cristalino do sal dissódico do ácido n-(5-saliciloil)-8-aminocaprílico, composição farmacêutica, processo para preparar a forma i do sal dissódico do ácido n-(5-saliciloil)-8-aminocaprílico, processo para preparar um solvato de monoetanol do sal dissódico do ácido n-(5-saliciloil)-8-(...)
US7713929B2 (en) * 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
US8084420B2 (en) 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
EP1991575A1 (en) * 2006-02-21 2008-11-19 Novo Nordisk A/S Single-chain insulin analogues and pharmaceutical formulations thereof
WO2007121318A2 (en) 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Formulations for delivering insulin
EP2012817A2 (en) 2006-04-12 2009-01-14 Biodel, Inc. Rapid acting and long acting insulin combination formulations
EP2074140B8 (en) 2006-10-04 2015-10-28 Case Western Reserve University Fibrillation-resistant insulin and insulin analogues
EP3050568B1 (en) 2007-03-13 2020-12-02 JDS Therapeutics, LLC Methods and compositions for the sustained release of chromium
JP5526018B2 (ja) * 2007-03-21 2014-06-18 エミスフェアー・テクノロジーズ・インク アリルオキシおよびアルキルオキシ安息香酸送達薬剤
US20100120660A1 (en) * 2007-04-30 2010-05-13 Per Balschmidt Highly concentrated insulin solutions and compositions
WO2009002867A2 (en) 2007-06-26 2008-12-31 Nutrition 21, Inc. Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
CA2702892C (en) 2007-10-16 2017-02-28 Biocon Limited An orally administerable solid pharmaceutical composition and a process thereof
WO2009059188A1 (en) 2007-11-02 2009-05-07 Emisphere Technologies, Inc. Method of treating vitamin b12 deficiency
NZ590792A (en) 2008-07-31 2012-12-21 Univ Case Western Reserve Halogen-stabilized insulin
CN102209541B (zh) 2008-09-08 2016-05-18 小利兰·斯坦福大学托管委员会 醛脱氢酶活性调节剂和其使用方法
AU2009305472B2 (en) 2008-10-17 2013-12-19 Sanofi-Aventis Deutschland Gmbh Combination of an insulin and a GLP-1 agonist
US8389522B2 (en) 2008-10-28 2013-03-05 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase and methods of use thereof
EP2391217A4 (en) 2009-01-28 2015-05-20 Smartcells Inc SYNTHETIC CONJUGATES AND USES THEREOF
US9050370B2 (en) 2009-01-28 2015-06-09 Smartcells, Inc. Conjugate based systems for controlled drug delivery
CA2750074A1 (en) 2009-02-12 2010-08-19 Proyecto De Biomedicina Cima, S.L. Use of cardiotrophin-1 for the treatment of metabolic diseases
US9060927B2 (en) 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
CA2754950A1 (en) 2009-03-20 2010-09-23 Smartcells, Inc. Terminally-functionalized conjugates and uses thereof
EP2554183B1 (de) 2009-11-13 2018-04-04 Sanofi-Aventis Deutschland GmbH Pharmazeutische Zusammensetzung umfassend einen GLP-1-Agonisten, ein Insulin und Methionin
DK2498801T3 (en) 2009-11-13 2018-05-07 Sanofi Aventis Deutschland PHARMACEUTICAL COMPOSITION INCLUDING desPro36Exendin-4 (1-39) -Lys6-NH2 AND METHIONIN
EP2599494A1 (en) 2010-01-11 2013-06-05 Healor Ltd. PKC inhibitors for the treatment of inflammatory disease or disorder
TWI590829B (zh) * 2010-02-24 2017-07-11 艾米斯菲爾科技股份有限公司 口服ｂ１２的療法
KR101823320B1 (ko) 2010-08-30 2018-01-31 사노피-아벤티스 도이칠란트 게엠베하 제２형 진성 당뇨병 치료용 약제를 제조하기 위한 ａｖｅ００１０의 용도
JP6049087B2 (ja) 2010-09-30 2016-12-21 ソルヴェイ（ソシエテ アノニム） 天然起源のエピクロロヒドリンの誘導体
WO2012115641A1 (en) 2011-02-23 2012-08-30 Elona Biotechnologies Lis-pro proinsulin compositions and methods of producing lis-pro insulin analogs therefrom
EP4070801A1 (en) 2011-03-01 2022-10-12 Nutrition 21, LLC Compositions of insulin and chromium for the treatment and prevention of diabetes, hypoglycemia and related disorders
US10457659B2 (en) 2011-04-29 2019-10-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
PT2750699E (pt) 2011-08-29 2015-11-03 Sanofi Aventis Deutschland Acelerómetro pendular
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
CN104010652A (zh) 2011-10-27 2014-08-27 卡斯西部储备大学 超浓缩的速效胰岛素类似物制剂
WO2014004278A1 (en) * 2012-06-26 2014-01-03 The Curators Of The University Of Missouri Photocleavable drug conjugates
EP2877200B1 (en) 2012-07-17 2019-05-08 Case Western Reserve University O-linked carbohydrate-modified insulin analogues
US9700599B2 (en) 2012-11-13 2017-07-11 Adocia Rapid-acting insulin formulation comprising a substituted anionic compound
US9707276B2 (en) 2012-12-03 2017-07-18 Merck Sharp & Dohme Corp. O-glycosylated carboxy terminal portion (CTP) peptide-based insulin and insulin analogues
JP6111475B2 (ja) 2012-12-19 2017-04-12 ウォックハート リミテッド ヒトインスリン又はその類似体もしくは誘導体を含む安定な水性組成物
BR112015013223A2 (pt) 2012-12-26 2017-07-11 Wockhardt Ltd composição farmacêutica
CN105358531B (zh) 2013-03-14 2017-11-14 利兰-斯坦福大学初级学院的董事会 线粒体醛脱氢酶‑2调节剂和其使用方法
TW201605489A (zh) 2013-10-25 2016-02-16 賽諾菲公司 賴谷胰島素（ｉｎｓｕｌｉｎ ｇｌｕｌｉｓｉｎｅ）的穩定調配物
EP3185887B1 (en) 2014-08-26 2021-03-10 Merck Sharp & Dohme Corp. Method for preparing crystalline insulin or insulin analog compositions
KR102578030B1 (ko) 2014-12-12 2023-09-14 사노피-아벤티스 도이칠란트 게엠베하 인슐린 글라진／릭시세나티드 고정비 제형
TW201630622A (zh) 2014-12-16 2016-09-01 美國禮來大藥廠 速效胰島素組合物
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
JO3749B1 (ar) 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول
GB2564295A (en) 2016-02-11 2019-01-09 Nutrition 21 Llc Chromium containing compositions for improving health and fitness
AU2018275545B2 (en) 2017-06-01 2021-02-04 Eli Lilly And Company Rapid-acting insulin compositions
WO2019125879A2 (en) 2017-12-18 2019-06-27 Merck Sharp & Dohme Corp. Conjugate based systems for controlled insulin delivery
US11820805B2 (en) 2017-12-18 2023-11-21 Merck Sharp & Dohme Llc Conjugate based systems for controlled insulin delivery
BR112022007593A2 (pt) 2019-10-25 2022-08-23 Cercacor Lab Inc Compostos indicadores, dispositivos que compreendem compostos indicadores e métodos de fabricação e uso dos mesmos
GB2610490A (en) 2020-03-31 2023-03-08 Protomer Tech Inc Conjugates for selective responsiveness to vicinal diols
MX2023005935A (es) 2020-11-19 2023-05-29 Protomer Tech Inc Compuestos aromaticos que contienen boro y analogos de insulina.
WO2023225534A1 (en) 2022-05-18 2023-11-23 Protomer Technologies Inc. Aromatic boron-containing compounds and related insulin analogs

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3060093A (en) * 1957-07-18 1962-10-23 Nordisk Insulinlab Slowly acting insulin preparation in crystalline form and method of preparation
FI78616C (fi) * 1982-02-05 1989-09-11 Novo Industri As Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt.
US4608634A (en) * 1982-02-22 1986-08-26 Texas Instruments Incorporated Microcomputer with offset in store-accumulator operations
DK347086D0 (da) * 1986-07-21 1986-07-21 Novo Industri As Novel peptides
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
DE3717370A1 (de) * 1987-05-22 1988-12-01 Hoechst Ag Mischkristalle aus insulin und insulinderivaten, verfahren zur herstellung dieser mischkristalle, diese mischkristalle enthaltende pharmazeutische mittel und ihre verwendung zur behandlung von diabetes mellitus
ATE93238T1 (de) * 1988-07-20 1993-09-15 Novo Nordisk As Menschliche insulinanalage und zubereitungen daraus.
HUT56857A (en) * 1988-12-23 1991-10-28 Novo Nordisk As Human insulin analogues
IL93282A (en) * 1989-02-09 1995-08-31 Lilly Co Eli Insulin analogues
ATE176482T1 (de) * 1993-06-21 1999-02-15 Novo Nordisk As Asp-b28-insulinkristalle
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations

Also Published As

Publication number Publication date
GB2291427B (en) 1998-09-16
RO113530B1 (ro) 1998-08-28
KR100382326B1 (ko) 2003-07-07
AU2168095A (en) 1996-01-04
YU39695A (sh) 1997-08-22
RU2152399C2 (ru) 2000-07-10
AT408720B (de) 2002-02-25
ES2091727B1 (es) 1998-02-01
DK173015B1 (da) 1999-11-15
JP2001199899A (ja) 2001-07-24
HU227240B1 (en) 2010-12-28
RS49577B (sr) 2007-04-10
JP3171541B2 (ja) 2001-05-28
MY115631A (en) 2003-08-30
NZ272359A (en) 1996-10-28
PT101722B (pt) 1997-02-28
US5474978A (en) 1995-12-12
TW421596B (en) 2001-02-11
ATA101695A (de) 2001-07-15
IL114151A (en) 2000-09-28
CO4410203A1 (es) 1997-01-09
BR9502795A (pt) 1996-03-12
FI952931A (fi) 1995-12-17
IE950436A1 (en) 1995-12-27
ZA954943B (en) 1997-09-14
ES2091727A1 (es) 1996-11-01
NL1000566C2 (nl) 1996-12-03
SE9502167D0 (sv) 1995-06-14
NL1000566A1 (nl) 1995-12-18
NO952357D0 (no) 1995-06-14
KR960000924A (ko) 1996-01-25
JPH083067A (ja) 1996-01-09
PL181310B1 (pl) 2001-07-31
FR2741078A1 (fr) 1997-05-16
FR2721214A1 (fr) 1995-12-22
HUT73186A (en) 1996-06-28
SE509052C2 (sv) 1998-11-30
IT1276723B1 (it) 1997-11-03
LU88626A1 (fr) 1996-02-01
BE1009408A5 (fr) 1997-03-04
CN1105576C (zh) 2003-04-16
PT101722A (pt) 1995-12-29
IL114151A0 (en) 1995-10-31
NO952357L (no) 1995-12-18
NO322128B1 (no) 2006-08-21
PL309098A1 (en) 1995-12-27
CA2151560A1 (en) 1995-12-17
AU694501B2 (en) 1998-07-23
CZ287484B6 (en) 2000-12-13
IE68853B1 (en) 1996-07-24
RU95110109A (ru) 1997-05-10
GB2291427A (en) 1996-01-24
CN1122248A (zh) 1996-05-15
ITMI951278A1 (it) 1996-12-14
FR2721214B1 (fr) 1997-09-26
CZ154295A3 (en) 1996-02-14
CA2151560C (en) 2000-05-09
PE19496A1 (es) 1996-06-01
GB9512038D0 (en) 1995-08-09
GR1003004B (el) 1998-11-05
DE19521720A1 (de) 1995-12-21
CH689250A5 (de) 1999-01-15
GR950100229A (en) 1996-02-29
CH689935A5 (de) 2000-02-15
FI952931A0 (fi) 1995-06-14
FR2741078B1 (fr) 1998-08-07
HU9501716D0 (en) 1995-08-28
HK1015138A1 (en) 1999-10-08
SE9502167L (sv) 1995-12-17
ITMI951278A0 (it) 1995-06-14
DE19521720B4 (de) 2009-09-03
FI118207B (fi) 2007-08-31
DK67795A (da) 1995-12-17
SI9500200A (en) 1996-02-29

Similar Documents

Publication Publication Date Title
UA26874C2 (uk) Пареhтеральhа фармацевтичhа композиція
TW347334B (en) Monomeric insulin analog compositions
HUP0100243A2 (hu) Inzulint és/vagy inzulin-analógokat és azok származékait tartalmazó oldhatatlan készítmények, eljárás azok előállítására és alkalmazásuk a vércukor szintjének szabályozására
BR9205640A (pt) Dímero de apolipoproteína ai-milano, composiçao farmacológica, processo de preparaçao do dímero, uso deste na preparaçao de medicamentos e processo para o tratamento de aterosclerose e doenças cardiovasculares
EP1197220A3 (en) Therapeutic methods and compositions based on delta proteins and nucleic acids
BR9407508A (pt) Derivado de insulina composição farmaceutica e processo para o tratamento de diabete em um paciente com necessidade deste tratamento
DE69027989T2 (de) Il-3 MIT ZUSÄTZLICHEN CYSTEINRESTEN UND CHEMISCHE MODIFIKATIONEN DAVON
PT83278A (en) Process for the preparation of insulin analogues and of injectable insulin solutions containing the same
MX9703643A (es) Metodos para tratamiento de esclerosis multiple usando analogos de peptidos de proteina basica de mielina humana.
BR9710452A (pt) Anïïlogos de exendina processos para sua prepara-Æo e medicamentos contendo os mesmos
HUP0004169A2 (hu) Oldhatatlan inzulinkészítmények és eljárás ezek előállítására
NZ330700A (en) B27, B28, B29 (B chain) insulin derivatives having a rapid onset of action
IL82209A0 (en) Insulin preparation
AU6020099A (en) Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
ES2180511T3 (es) Formulaciones monodispersas de analogos de insulina acilados hexamericos.
DE69430868T2 (de) Verfahren und zubereitungen zur verzoegerung oder vorbeugung von autoimmun krankheiten
AU7148791A (en) The use of arginine as an immunostimulator
EP1127577A3 (en) Ligand for the c-kit receptor and methods of use thereof
MX9704738A (es) Analogos de peptido p277 y composiciones farmaceuticas que los contienen, metodo de diagnostico de diabetes mellitus dependiente de la insulina y uso de los mismos.
IL84484A0 (en) T-cell suppressor protein in pure form,its preparation by recombinant methods and pharmaceutical compositions containing it
AU652988B2 (en) Method for insuring adequate intracellular glutathione in tissue
STOUFFER et al. Reversible binding of ACTH to a glass surface
HK1026843A1 (en) Somatostatin and somatostatin agonists for treating insulin insensitivity and syndrome x.
JPS6416799A (en) H-pth (1-34) composition and its preparation
KR950013519A (ko) 골절 예방 및 치료용 약제